H epatitis E virus (HEV) is a small nonenveloped RNA virus from the Hepeviridae family. It is a main cause of acute hepatitis, which is usually a self-limiting infection. [1] [2] [3] In immunocompromised subjects HEV can become persistent or chronic and can lead to serious consequences such as fulminant hepatitis. 4 Although the main route of transmission is the fecal-oral route, vertical transmission and transmission through blood transfusion were also documented. HEV is usually diagnosed using serologic and molecular laboratory tests. This includes the detection of anti-HEV (immunoglobulin [Ig]G and IgM) in sera of infected patients using enzyme immunoassays, and HEV RNA in both sera and feces using real-time polymerase chain reaction (RT-PCR). 1, 3 Currently, the detection rates and seroprevalence of HEV is expected to increase due to the availability of sensitive assays compared to what was available earlier. 2, 3 infection since it was identified as a specific disease in the 1990s. 1 HEV is a major public health problem and a main cause of morbidity and mortality worldwide. 5 Approximately one-third of the world's population lives in HEVendemic areas. 1 The HEV incidence rate in the developing world is higher than that in the developed world, mainly due to sanitary conditions and frequent outbreaks instigated by the ingestion of feces-contaminated water. 1, 6, 7 HEV is considered the main cause of acute hepatitis outbreaks in developing countries. These usually occur after flooding in the monsoon season. 8 Outbreaks and sporadic cases were reported worldwide, including developed countries, where most of the cases are sporadic in nature. Generally in hyperendemic countries, the seroprevalence of HEV IgG antibodies among healthy blood donors may reach 45%, compared to lower rates in industrialized countries with some exceptions.
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HEV has four well-known genotypes. 9 Genotypes 1 and 2 infect humans only while Genotypes 3 and 4 infect humans and some animals and are transmitted zoonotically. 10 Genotype 1 is generally associated with fecal-oral transmission epidemics in Asia, while Genotype 2 is more prevalent in Africa. 11, 12 Recently, a new genotype (HEV 7)
was isolated from feces of Arabian camels (dromedaries) in the Arabian Peninsula. 13 Data on the seroprevalence of HEV antibodies in Qatar and the Gulf region are scarce. Two earlier studies of HEV in Qatar considered HEV as an imported infection, since almost all the patients were expatriates and were diagnosed within 8 weeks of arriving to Qatar. 14 Since Qatar's population is composed of more than 80% of expatriates coming from different countries including the hyperendemic countries such as India and Egypt, it is important to estimate the seroprevalence and to compare between different nationalities. The results can be useful also in alerting blood banks to the importance of HEV screening and to investigate possible transmission patterns in the country. To our knowledge, this study regarding the seroprevalence of anti-HEV from blood donations taken from apparently healthy blood donors is the first study of its kind in Qatar and has the largest sample size in the Gulf region. This study aims to estimate the seroprevalence of hepatitis E antibodies among healthy blood donors in Qatar and to explore the factors associated with positive HEV antibodies among healthy blood donors.
MATERIALS AND METHODS
Ethical compliance and blood sample collections A total of 5854 whole blood samples were collected in EDTA tubes from blood donations taken from healthy donors at the Blood Donor Unit at Hamad Medical Corporation over a period of 3 years (June 2013-May 2016). Samples were collected at a frequency of 2 to 3 days per week upon the availability of samples. Samples were transported and stored according to standard safety procedures. Samples were centrifuged and plasma was stored at 2808C. Importantly, HMC Institutional Review Board approval (Protocol 14292/14) was obtained before sample collection. Blood samples did not include names or other identifying information of the participants. Only general information (such as sex, age, and nationality) was collected.
Serologic testing
All samples were serologically tested for the presence of anti-HEV IgM and IgG. Only positive IgM samples were tested for the presence of HEV RNA as described below.
Detection of anti-HEV total IgM and IgG
All serum samples were screened for the presence of anti-HEV IgM and IgG using the (Wantai) enzyme-linked immunosorbent assay (ELISA) kits (Catalog No. WE-7196, HEV-IgM ELISA and Catalog No. WE-7296, HEV-IgG ELISA, Wantai Biological Pharmacy Enterprise Co.) according to the manufacturer's instructions. Based on literature, the HEV Wantai kits are one of the most available commercial kits used in seroprevalence studies. Borderline samples were repeated in duplicate; if one or both of the repeated test results were positive, the sample was considered positive for anti-HEV IgG. If both repeated test results were negative, the sample was considered negative. If after repetition the reading was still within borderline range, the result was considered as negative.
Detection of HEV RNA
RNA was extracted from 200-mL aliquots of serum using a standard commercial kit for viral RNA extraction from body fluids (QIAamp viral RNA mini kit, Qiagen) according to the manufacturer's instructions. Reverse transcription and amplification of HEV RNA (done all in one tube) were performed from 10 mL of the extracted RNA according to the manufacturer's instructions of a qualitative HEV RT-PCR kit (TaqMan ampliCube, Mikrogen GmbH) using a RT-PCR instrument (QuantStudio 6 Flex, Applied Biosystems). The limit of detection of the ampliCube HEV 2 is 36.13 IU/mL, determined by probit analysis (95% confidence interval [CI], 24-.8-78.16 IU/mL). Cycle thresholds (CT) were calculated according to the manufacturer's instruction. Samples with CT value above CT value of the negative control (39-45) were considered negative. It should be noted that the CT values of all of our four positive samples were less than the CT value of the positive control (<33).
Finally, to avoid contamination, extraction, preparation of master mix, and amplification and detection were performed in three separate rooms. HEV RNA viral load was calculated in copies per reaction and, according to the manufacturer's instruction, samples with CT of higher than that of negative controls were considered negative.
Statistical analysis
Seroprevalence was determined based on HEV antibodies (IgG and/or IgM) positive results. HEV status was defined as a binary variable with positive or negative IgG/IgM antibodies in blood donation plasma. Age calculated from date of birth was available for 5827 participants. Nationality was available for 5809; a total of 45 were with unknown nationality and classified as missing. Sex was missing for 19 of the 5854 blood donor samples.
Descriptive statistics (means, standard deviations [SDs]) were used to explore the characteristics of the study sample. Crosstabs and Pearson's chi-square were used for the bivariate analysis to examine the association between HEV status and potential individual associated factors. A multivariate logistic regression model was also used to examine the association between HEV antibody status (dependent variable) and all available independent variables including age, sex, and nationality. Year of sample collection was not used in the regression model because we were not able to detect a significant difference in HEV status by year of collection.
RESULTS
The relative distribution of blood donations by nationality showed that Qataris comprised the largest percentage of the donations. The number of donations belonging to Qataris was 1161 (20.0%) followed by Egyptians and Syrians. The mean 6 SD age of the tested donors was 36.6 6 9.3 years. Approximately 38.9% of the participating donors were aged 25 to 34 years. Only 152 (2.6%) of the samples belonged to females, while the rest were from males. Table 1 Table 2 shows the frequencies with 95% CIs. Table 3 outlines the distributions of HEV antibody seroprevalence, with the top ranks occupied by Sudanese and Pakistani residents with seroprevalences of 51.5 and 40.9%, respectively. Meanwhile, Qatar comes at a much lower seroprevalence of 11.5%. The prevalence of HEV antibody-positive cases among non-Qataris is nearly double that of Qataris (22.9% vs. 11.5%, respectively), with a significant statistical association (p < 0.001). There was a clear and consistent increase in HEV antibodies seroprevalence by age group as shown in Fig. 1 . The bivariate analysis (Table 3 ) yielded a significant association between HEV antibodies and both nationality and age, while there was no association with sex. We were also not able to detect any time trends when we compared seroprevalence by year of blood donation, 2013, 2014, 2015, and 2016 (20.2, 20.4, 20.9, and 21.3%, respectively). A multivariate logistic regression analysis was conducted to measure the association between HEV antibodies status as the dependent variable and suspected associated factors including age, sex, and nationality as explanatory factors. Age and nationality continued to be significantly associated with HEV status.
DISCUSSION
This study included the largest number of blood donations of its kind in the Gulf region. To our knowledge, all other studies targeting blood donations had a sample of less than 1000. 2 This should facilitate meaningful comparison among different nationalities living in Qatar. The HEV seroprevalence among blood donors in Qatar is Seroprevalence of HEV antibodies obtained from our study targeting health blood donations in Qatar was higher than some studies in countries of the developed world. In a study targeting US blood donors, the prevalence of HEV antibodies (IgG/IgM) was 7.7%. 25 In some
European countries, the prevalence of anti-HEV IgG among blood donors ranged from 4.9% in Southwest Switzerland 26 to 5.4% in Italy 27 to 13.6% 28 in upper Austria and 15.0% in Serbia. 29 However, there are some examples of very HEV high seroprevalence in some developed countries as demonstrated by a study conducted in the MidiPyr en ees region in southwestern France where HEV IgG was detected in 52.5% of the blood donor samples. 30 The high seroprevalence in Qatar might be expected due to the mixed population in Qatar where a large proportion of the population is coming from hyperendemic countries such as Egypt and the Indian subcontinent.
The difference between Qatari and non-Qatari participants and the age group differential was expected and similar to both previously mentioned Saudi studies conducted among male donors in Jeddah and Mecca. These two studies have shown an increased prevalence among non-Saudis compared to Saudis, except for the Europeans in the Jeddah study. Similarly, the HEV IgG seroprevalence 35 which is a bit higher than that of Egyptians in the current study. A population-based study in Egypt revealed an anti-HEV seroprevalence exceeding 60% in all age groups and peaking at 76% in the second decade. 35, 36 In this study, anti-HEV IgM was detected in 34 donors, suggesting the presence of silent acute HEV infection at the time of donation. Indeed, viremia was confirmed in four of 34 IgM-positive donors by RT-PCR, suggesting a viremia ratio of 1:1463 among blood donors in Qatar, a ratio that is higher than expected ( Table 4 ). As we only tested for HEV RNA in anti-IgM-positive donors, this ratio is possibly underestimated. That is, anti-HEV IgM might not reach detectable levels at early stages of infection (window period), where RNA usually peaks; thus, many viremic cases may have been missed in our study. 37, 38 Further, another reason why HEV RNA was not detected in the rest of the IgM-positive donors is that IgM stayed detectable during convalescence (3-6 months after onset). Therefore, relying on antibody detection alone could lead to misdiagnosis of acute HEV in many infected cases. Several studies have indicated that RNA detection of HEV could be of particular importance, especially in cases that involve blood donation or transfusion. Accordingly, HEV RNA detection is the gold standard to uncover viremia. [38] [39] [40] Some of the limitations that may have affected the current study include the fact that repetitive donors giving more than one donation cannot be ruled out. However, we see no reason to assume that the donation patterns of the HEV antibody-positive donors are different from HEVantibody negative donors.
Another limitation is the lack of information about some potential risk factors such as education, socioeconomic status, period of residency in Qatar, travel history, transfusion history, and dialysis history. Such information about contributing factors and potential confounders were not available since limited information regarding the characteristics of the donors was available and collected by the blood bank. This has left some important questions unanswered.
HEV seroprevalence defined by a positive HEV antibodies was high in Qatar. The Qatari healthy blood donors have a much lower prevalence than the non-Qataris. Based on the established seroprevalence and since there was no significant difference between the 4 years of blood donations tested in this study, we may conclude that HEV is becoming endemic in Qatar. Because we documented here a silent acute HEV either by positive HEV RNA or by IgM in blood donors, blood banks in Qatar should consider adding HEV testing to the test battery already performed for donors, particularly in the case of blood transfusion to immunocompromised patients or pregnant women.
